REVISTA Nº 36
The best ophthalmology, with the the utmost safety
A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.
RESEARCHER: Dr. Jesús Merayo Lloves ACTIVO A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to […]
“Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye”
RESEARCHER: Dr. Jesús Merayo Lloves RECLUTANDO “Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye” INDICATION: Pacientes con ojo seco leve o moderado TREATMENT: AVX-012 PROMOTOR: Avizorex Pharma
A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)
RESEARCHER: Prof. Luis Fernández-Vega Sanz RECLUTANDO A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD) INDICATION: Pacientes con degeneración macular asociada a la edad (DMAE húmeda). TREATMENT: OPT-302 PROMOTOR: […]
Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC)
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz ACTIVO Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC) INDICATION: Patients with polypoid choroidal vasculopathy TREATMENT: Aflibercept PROMOTOR: AIBILI
Macular edema secondary to occlusion of the central
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz RECLUTANDO INDICATION: Macular edema secondary to occlusion of the central TREATMENT: Aflibercept PROMOTOR: Bayer AG
Double masked SYL1001 study in patients with moderate or severe dry eye disease
RESEARCHER: Dr. Jesús Merayo Lloves RECLUTANDO Double masked SYL1001 study in patients with moderate or severe dry eye disease INDICATION: Patients with moderate to severe dry eye TREATMENT: SYL1001 PROMOTOR: SYLENTIS
Artículo del Dr. Ignacio Rodriguez Uña
Tercer Premio THEA-S.E.G. de Investigación en Oftalmología 2017 a las mejores publicaciones en Glaucoma en el XII Congreso de la Sociedad Española de Glaucoma en Valencia.
THE FUNDACIÓN FERNÁNDEZ-VEGA, AT ASOCIACIÓN NORA
A team travelled there this morning and will remain there until early afternoon; they expect to perform over thirty eye examinations in this period of time.
THE FUNDACIÓN FERNÁNDEZ-VEGA PERFORMS EYE EXAMINATIONS IN CAMBODIA
The team of volunteers, constituted by two physicians and an optometrist, arrived yesterday from the Asian country after having checked the eyesight of 450 people.
